discovery of senescence induced by a PKD effective drug suggests a new area of therapeutic investigation in this disease.
Background
The pathobiology of polycystic kidney disease (PKD) at the molecular level involves aberrant cell cycle progression in a similar fashion to cancer, such that PKD has been labeled 'neoplasia in disguise' [1] . However, PKD is associated with increased levels of apoptosis [2] , whereas the opposite is true of cancers which are in nearly all instances characterized by suppression of apoptosis [3] . In fact, the goal of cancer therapy is to increase apoptosis in malignant cells, whereas in PKD, such an increase in an already amplified process is likely detrimental [4] .
While possessing pleiotropic effects, the cyclin-dependent kinase (CDK) inhibitor p21 waf1/cip1 generally suppresses cell proliferation and decreases apoptosis in mesenchyme-derived cells [5] . Polycystin-1, whose gene is mutated in 85% of human autosomal dominant PKD (ADPKD), increases expression of p21 [6] , and p21 is decreased in human and a rat model of PKD [7] ; these findings are consistent with the observed augmentation of both cell proliferation and apoptosis in this disease.
While the chemotherapeutic agent and CDK inhibitor roscovitine was recently shown to exert salutary effects on a mouse model of PKD [8] , the mechanism by which this drug exerts these effects is not known. In particular, it is unclear how this kinase inhibitor can have beneficial effects in cancer, in which the goal is to kill the offending malignant cells, and in PKD, where the objective is to prevent proliferation and decrease apoptosis. We now show that roscovitine has opposing outcomes on renal tubular epithelial (RTE) cell apoptosis depending on its concentration. In addition, we show that the mechanism of roscovitine's beneficial effect in PKD is likely through induction of cell senescence, rather than apoptosis. Our work will lead to careful assessment of dose response while using this drug in both clinical and research settings, and will open new avenues of therapeutic investigation for PKD focusing on the induction of RTE replicative senescence.
Methods

Materials and Cell Culture
Roscovitine was purchased from Sigma (St. Louis, Mo., USA). The Senescence Detection Kit was purchased from Biovision (Mountain View, Calif., USA). MDCK and HEK293 cells were obtained as kind gifts from Dr. John Payne and Dr. Elva Diaz, respectively, at the University of California, Davis. WT 9-7 cells (derived from a human ADPKD proximal tubule cyst) were obtained from ATCC; all cell lines were maintained in Dulbecco's media, 10% fetal bovine serum and 1% Pen/Strep. Mouse monoclonal antirecombinant full-length p21 Waf1/Cip1 antibody was obtained from Upstate Biotechnology (Lake Placid, N.Y., USA), p53 antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, Calif., USA), and mouse anti-PARP purified antibody and apoptosis detection kit were obtained from BD Biosciences (San Diego, Calif., USA). Phospho-p53 antibody (pSer 15 ), phospho-Akt antibody (pSer 473 ) and phospho-Bad antibody sampler kit were obtained from Cell Signaling Technology (Danvers, Mass., USA). Goat anti-mouse and goat anti-rabbit horseradish peroxidaseconjugated IgG were obtained from Bio-Rad (Richmond, Calif., USA). Mouse anti-␤ -actin monoclonal antibody was from SigmaAldrich (St. Louis, Mo., USA). ECL Western blotting detection reagents were obtained from Amersham Biosciences (Little Chalfont, UK). For roscovitine treatment, cells were seeded for 24 h before treatment and roscovitine was added to the cells in serumcontaining media and incubated for 24 h.
Immunoblotting
Western blotting was performed as previously described [7] .
Assessment of SA-␤ -Galactosidase Activity as a Measure of Senescence [9] The vendor's instructions were followed. Briefly, cells were seeded 24 h before roscovitine treatment and roscovitine was added to the cells with serum-containing media for an additional 24 h. Cells were incubated with staining mixture overnight and observed under a microscope under visible light. Blue-stained cells and the total number of cells were counted to calculate the percentage of cells expressing ␤ -galactosidase. After data acquisition, raw images were opened with Powerpoint and images were processed with the built-in adjustment function of 'auto levels', 'auto contrast', and 'auto color'. Contrast was adjusted in panels showing blue staining for better visualization. No further image manipulation occurred.
Caspase Assay
The CaspACE assay kit (Promega, Madison, Wisc., USA) was utilized following the manufacturer's instructions. Briefly, cells were harvested, washed, and equal protein quantities were incubated with the DEVD-pNA caspase-3 substrate in caspase assay buffer. Color development was measured at 405 nm.
Results
Roscovitine has been shown to be effective in cancer and, more recently, in murine PKD. This is enigmatic, since cancer therapeutics generally act through induction of apoptosis, while ADPKD is already a highly apoptotic disease in which this biochemical event likely contributes to its pathogenesis [reviewed in 10 ]. We have previously shown that p21 is increased in MDCK cells in a roscovitine dose-dependent manner from 1 to 10 g/ml [7] . In order to determine the consequence of roscovitine incubation on RTE cells over a wider range of concentrations, we incubated MDCK cells growing in 10% serum-containing media ('complete' media) with roscovitine at 'low' (5-10 g/ml) and 'high' (20-40 g/ml) concentrations and examined levels of both PARP cleavage, as a measure of apoptosis, and p21, a CDK inhibitor with antiapoptotic effects [11, 12] . At high concentrations, roscovitine resulted in PARP cleavage, while at low concentrations, there was no apoptosis and p21 was elevated ( fig. 1 a) . Surprisingly, there was an abrupt change in both p21 levels and apoptosis between the 5-and 20-g/ml concentrations of roscovitine, an event which was confirmed in an additional RTE 'normal' cell line, human HEK293 cells ( fig. 1 b) , and an ADPKD human cell line (WT 9-7) ( fig. 1 c) ; the latter cells showed different sensitivity to roscovitine.
To confirm that apoptosis is indeed occurring at high, but not low, roscovitine concentrations, we repeated the MDCK cell experiment at smaller concentration increments and examined activation of caspase-3 as another measure of apoptosis. Caspase-3 activity was significantly increased from control cells at 16 and 20 g/ml roscovitine ( fig. 2 ), a finding which paralleled PARP cleavage (compare fig. 1 a) and was inversely correlated with p21 levels (lower panel in fig. 2 ) confirming apoptosis with high-dose, but not low-dose, roscovitine.
The role of apoptosis in PKD has been intensively investigated, yet there exists conflicting data on this point. While in general it appears that inhibition of apoptosis in PKD has salutary effects [13] [14] [15] , there is also data showing that the induction of apoptosis associated with mTOR inhibition by rapamycin results in a reduction of cyst growth in mouse models of PKD [16, 17] . Thus, while the function of apoptosis in the disease is controversial, the induction of replicative senescence, the state of irreversible cell cycle arrest, has the incontrovertible potential to beneficially modulate the aberrant cell proliferation seen in this disease. In addition, senescence is triggered by p21 [18] [19] [20] , which we show is increased only at low-dose roscovitine ( fig. 1 ). Thus, we examined roscovitine-stimulated cells for SA-␤ -galatosidase activity as a biomarker for senescence [9] . We utilized MDCK cells as well as the human ADPKD cell line (WT 9-7). While there was minimal blue staining in the control cells, staining increased progressively in cells incubated with roscovitine ( fig. 3 ), indicating that these low doses of roscovitine caused these cells to become senescent [9] . At high roscovitine concentrations ( 1 10 g/ml in MDCK and 1 3 g/ml in WT 9-7 cells), cell staining could not be accomplished since the cells became detached from the plate, consistent with the apoptotic phenotype described earlier ( fig. 1 ). Thus, low-dose treatment of RTEs with roscovitine causes them to enter the state of replicative senescence, whereas, as shown previously, high dose results in apoptosis.
In order to ascertain the mechanism by which these disparate effects occur, we next examined proteins in ad- dition to p21 which are involved in both DNA damage/ repair and apoptosis signaling cascades. Upon DNA damage, ATM is activated as a sensor of damage leading to its phosphorylation, which subsequently leads to phosphorylation and stabilization of p53 and phosphorylation of Akt, presumably in an attempt to repair this damage [21, 22] . Active Akt and p21 are responsible for the antiapoptotic state which is necessary for DNA repair. MDCK cells exposed to low-dose roscovitine for 24 h, which we have shown become senescent, show evidence of DNA damage as indicated by phosphorylation of ATM, p53 and Akt, while cells exposed to high-dose roscovitine, which become apoptotic, did not result in activation of the DNA damage/repair pathway ( fig. 4 ) . Nonphosphorylated p53, the inactive form, did not show any changes with high-dose roscovitine.
Examination of apoptotic proteins was next undertaken. After 24 h of high-dose roscovitine, the antiapoptotic proteins XIAP, Bcl-2, and phospho-Bad were decreased, yet the proapoptotic protein Bax was augmented in MDCK cells but not significantly altered in WT 9-7 cells ( fig. 5 ), consistent with a prior report of the role of Bax in roscovitine-mediated apoptosis in cancer cell lines [23] . Again, the sharp demarcation between low-and highdose roscovitine was evident in the expression of these signaling proteins.
Discussion
The CDK inhibitors, both endogenous (for example, p21) and synthetic (for example, roscovitine), have shown promise in the treatment of cancer [reviewed in 5 ], and more recently, of ADPKD [8] . While this is not surprising given that both diseases are characterized by excessive cell proliferation, it is unexpected in that these diseases are at opposite ends of the apoptosis spectrum: apoptosis being desirable in cancer chemotherapy, yet detrimental in PKD. In this study, we sought to determine how roscovitine can have these disparate effects yet be effective in both diseases. Our results indicate that this drug has pleiotropic effects in RTE cells over a quite narrow range of concentrations, being senescence-inducing and antiapoptotic at low concentrations, and apoptosis-inducing at higher concentrations.
Since p21 is in general an antiapoptotic protein [11, 12] , and because we have previously shown that p21 is decreased in PKD and increased in MDCK cells exposed to roscovitine [7] , it was logical to expect that p21 may be dictating, or at least functioning as a read-out of, the disparate roscovitine effects. Our finding that p21 correlates with antiapoptosis across all concentrations suggests that upregulation of p21 is a mechanism by which roscovitine exerts its varied effects. Further examination of other proand antiapoptotic signaling molecules has shown that the profile of expression of these proteins parallel the apoptotic changes in the cells. The Bcl-2 family is comprised of proapoptotic members such as Bad and Bax as well as an- MDCK and WT 9-7 cells were grown to confluence in 10% serum-containing media (complete media without roscovitine) and roscovitine was added at concentrations indicated for 24 h, and subsequently the cells were lysed and immunoblotted with the antibodies indicated. Shown is a representative experiment of at least three repetitions.
tiapoptotic proteins such as Bcl-2; these proteins regulate the intrinsic apoptotic pathway. The oncogene Bcl-2 exerts a survival function and thus blocks cell death in response to a variety of apoptotic stimuli, while the proapoptotic Bax [23] is maintained in an inactive conformation through direct interactions with the antiapoptotic Bcl-2 protein.
We show that high-dose, but not low-dose, roscovitine decreased Bcl-2 such that Bax can be released to initiate apoptosis [24, 25] . Our data is consistent with that in another study which demonstrated that high levels of Bcl-2 prevent apoptosis as well as cyst formation in MDCK cells [4] . Furthermore, because the level of Bad, another proapoptotic member of the Bcl-2 family, was slightly decreased, we further tested the level of phosphorylated Bad (the active form) and found that it was more markedly decreased at high-dose roscovitine in both canine and human cell lines ( fig. 5 ); this finding is consistent with prior studies showing that several kinases, including Akt, phosphorylate Bad and promote survival [26, 27] . Thus, our studies indicated that low doses of roscovitine likely induce minor repairable damage to cells, which in turn cause activation of ATM, p53, and p21, and activate the Akt pathway, which prevents cells from entering the apoptosis pathway rather than the survival pathway. As a result, cells enter the permanent cell cycle arrest stage, or replicative senescence, which of course is an ideal result for a potential PKD therapeutic and a novel finding of our study. The role of p21 as an indicator of apoptosis or senescence was confirmed in another human primary cell line, WT 9-7. However, these cells were more sensitive to the effect of roscovitine, causing p21 induction, apoptosis, and senescence at lower doses than the other cell lines examined. As in MDCK cells, antiapoptotic proteins such as Bcl-2 and Bax were decreased at apoptosis-inducing doses of roscovitine, yet the proapoptotic molecule Bax, although slightly increased, was not as pronounced. Although apoptosis occurs in WT 9-7 at a lower dose than in MDCK cells, the profile of proteins in the apoptosis pathway is similar, and the decreased level of p21 associated with apoptosis indicated that these proteins likely contribute to the observed apoptosis. This finding strongly suggests that only a low dose of roscotivine, sufficient for RTE cells to enter the senescence but not the apoptotic pathway, will be effective in human PKD treatment.
In the recent study reporting a salutary effect of roscovitine in murine PKD, neither serum nor urine concentrations of drug were measured [8] . However, an approximation of the urine concentration to which RTEs are exposed can be made based on published pharmacokinetic data [28] . Using these data, which showed that 0.02% of the administered roscovitine dose was excreted into the urine for up to 24 h, and using the described dose of 50 mg/kg [8] in a mouse of 20-30 g urinating 0.5-1 ml/24 h (http://www.jhu.edu/animalcare/Mouse.HTM), the calculated concentration of roscovitine in the urine in those animals is at most 0.3-0.4 g/ml; for 150 mg/ml, the calculated concentration is 0.9-1.2 g/ml. These concentrations are well within the low concentration of roscovitine in our study and thus could be expected to result in therapeutic senescence rather than apoptosis of RTE cells.
Our finding that an effective PKD therapeutic intervention results in the induction of senescence is consistent with the known role of p21 in this disease. It has been shown that p21 is induced by the product of the Pkd1 gene, polycystin-1 [6] , and work from our laboratory has shown that p21 is attenuated in human disease [7] . That low-dose roscovitine induces senescent markers in association with p21 augmentation is consistent with the known role of p21 in causing replicative senescence and its absence in avoiding this fate [18] [19] [20] 29] , and suggests that these events are mechanistically related. In addition, our finding that senescence occurs with use of an effective drug suggests that senescence may be a mechanism by which normal tubular cells (i.e. those with intact p21) are prevented from assuming a cystic phenotype. Furthermore, induction of the senescent state by low-dose roscovitine, as we describe here, explains the observed (and tantalizing) long-lasting nature of roscovitine in arresting murine PKD progression [8] .
Our data provide an explanation of how a CDK inhibitor can be effective in both PKD and cancer, diseases with opposite degrees of apoptosis, with the level of p21 being an indicator as to whether cells enter either the replicative senescence or apoptosis pathway. In addition, our finding of senescence induction may explain how it is that early treatment with roscovitine leads to lasting effects. In light of our findings, caution should be used in future studies with roscovitine such that the range of concentration for a particular disease is appropriate in light of this drug's function in apoptosis and senescence. In addition, further work should be directed at the promotion of senescence, by therapeutic or other means, as a potential therapeutic intervention in ADPKD.
